10:02 AM EST - Helix BioPharma Corp. : announced that it has received approval for its investigational new drug application from the United States Food and Drug Administration to perform its planned U.S. Phase I clinical safety and tolerability study of its lung cancer drug candidate L-DOS47. Helix BioPharma Corp.
shares T.HBP are trading up $0.12 at $2.85.
